IDH1 and glioblastoma: Nonetheless, if our method’s robustness is further supported outside of our current cross-validation study, such an MRI-based classifier capable of distinguishing poor surviving Group 1 IDH-wildtype glioblastoma patients from longer surviving Group 2 IDH-wildtype glioblastoma patients could have an immediate influence on patient care.